NCT01999764View on ClinicalTrials.gov

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
Impaired Dark Adaptation
Interventions
DRUG

QLT091001

QLT091001 administered orally at multiple time points.

OTHER

Placebo

Placebo is administered orally at multiple time points.

Trial Locations (7)

75231

Retina Foundation of the Southwest, Dallas

77030

Retina Consultants of Houston, Houston

78731

Keystone Research Ltd., Austin

90701

Sall Research Medical Center, Artesia

93103

California Retina Consultants, Santa Barbara

98004

Proliance Surgeons Inc., Seattle

02114

Ophthalmic Consultants of Boston, Boston

All Listed Sponsors
lead

QLT Inc.

INDUSTRY

NCT01999764 - Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation | Biotech Hunter | Biotech Hunter